Investigating Out of Specification (OOS)Test Results
July 18, 2023 | 10:15 – 5:15PM
BREAKING NEWS: FDA updates testing principles in their final OOS guidance (May 2022). The time has never been greater to stay up-to-speed with current regulatory thinking. With this release, it is critical to unpack what this means for you and your organization. In addition, FDA, ICH and USP all recognize OOS as top priority in the drug development process, and each have respective guidance, albeit interpretation is left to industry. This training gives you up-to-the-minute insight into new regulations and industry trends and showcases how leading companies investigates and documents OOS test results.
Delivered by Industry’s Leading SMEs in the QC Laboratory Environment Covering:
- Unpack FDA’s Investigating OOS Test Results for Pharmaceutical Production (May ’22) – Understand What This Means for You
- Develop a Science-Based and Risk-Based Investigation Plan to Assess Test Results
- Document An OOS Investigation to Meet Regulatory Expectations – Trials and Tribulations
- Conduct a Root Cause Analysis and Establish CAPA to Avoid Regulatory Violations
- Master the Responsibilities of the Analyst to Achieve Accurate Laboratory Test Results
- Understand the Responsibilities of the Laboratory Supervisor
- Examine the Raw Data and Verify the Calculations
- Evaluate the Performance of the Test Method
- Understand the Art of Retesting and Resampling
- Learn Tips to Reduce and OOS and OOT Test Results
This event is also appropriate to business development and sales managers that offer innovative solutions for QC laboratory management, validation departments, data collection and statistics.
Personnel in the Following Environments Should Attend:
QA/QC
Scientist
Chemist
Laboratory Management
Validation
Regulatory Affairs
Data Integrity